SEC Form 4 · accession 0001209191-19-003550

NovoCure Ltd · NVCR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Operating Officer

Period of report

Jan 10, 2019

Accepted (ET)

Jan 14, 2019 · 4:34 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001645113

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Ordinary Shares^F1	Jan 10, 2019	M	54,930	$14.37	A	201,488	D
Ordinary Shares^F2	Jan 10, 2019	S	20,880	$40.469	D	180,608	D
Ordinary Shares^F3	Jan 10, 2019	S	34,050	$41.14	D	146,558	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Options to Buy Ordinary Shares^F4	$14.37	Jan 10, 2019	M	54,930	D	—	Feb 23, 2025	Ordinary Shares	54,930	37,391	D

F1These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi.
F2On January 10, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 20,880 shares in multiple trades at prices ranging from $40.00 to $40.99. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F3On January 10, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 34,050 shares in multiple trades at prices ranging from $41.00 to $41.45. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
F4Fully vested as of the date hereof.